Dishman Pharmaceuticals and Chemicals Ltd Formerly known as Dishman Pharmaceuticals & Chemicals LimitedDishman Carbogen Amcis Limited. Dishman Pharmaceuticals and Chemicals Limited, formerly Dishman Pharmaceuticals and Chemicals Limited, operates as an outsourcing partner for the pharmaceutical industry. The Company manufactures and supplies intermediates, fine chemicals and various products for pharmaceutical, cosmetic and related industries. The Company's segments include Contract Research & Contract Manufacturing (CRAMS), and Bulk Drugs, Intermediates, Quats, Specialty Chemicals and Traded Goods. The Company's CRAMS business segment caters to the requirements of multinational pharmaceutical companies across the world. The Company's product portfolio includes Active Pharmaceutical Ingredients (APIs), High Potent APIs, Intermediates, Phase transfer catalysts, Lanolin-related products, and Antiseptic and disinfectant formulations. Its business units include Generic API, Dishman Specialty Chemicals, and Dishman Care.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.